PharmaQ
PharmaQ A.E. is a privately held Greek pharmaceutical company (founded 2008, IASIS PHARMA group member) that develops and distributes OTC drugs, medical devices, natural remedies, and self-care products exclusively through pharmacies in Greece and Cyprus, serving doctors, pharmacists, and consumers across eight therapeutic categories.
- Company typePrivate
- Founded2008
- HeadquartersKoropi, Greece
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PharmaQ does
PharmaQ A.E. is a privately held Greek pharmaceutical company (Société Anonyme) founded in 2008 in Athens and headquartered in Koropi, Attica. Since 2010 it has operated as a member of the IASIS PHARMA group, a Greek pharmaceutical conglomerate. The company markets 27 products across eight therapeutic categories — Allergology, Self-care, Gastroenterology, General Medicine, Dermatology, Pediatric, Oral Hygiene, and Otorhinolaryngology — comprising OTC (non-prescription) pharmaceuticals, medical devices, naturally derived remedies, and self-care products. Distribution is exclusively through pharmacies in Greece and Cyprus, with stated intent to extend into broader European and international markets via partnerships with international pharmaceutical principals.
The portfolio is built around a small number of differentiated formulations: liposomal microencapsulated iron pyrophosphate (Ferrum Iasis), a Melatonin/Valerian/Hops combination sleep product (JustSleep, Gold Award winner at the 2018 Best in Pharmacy Awards), and the EMA-approved Chios Mastiha herbal line (Mastiha var.Chia in capsules, powder sachets, and a regenerative gel). Recent additions include Qpain®, a topical diclofenac cutaneous solution launched in October 2023, and the Chios Mastiha Powder line launched in November 2023. PharmaQ also represents and distributes products from multiple international partners (DMG, Giuliani, Ceutics, Quies, Hartington, Pharmacosmetic-Diafarm, Temmler, Pharmacure) in the Greek market.
The go-to-market is a classic specialty pharma field-sales model: a dedicated sales force targets doctors and pharmacists, supported by active participation in Greek medical congresses (HellasPHARM, PHARMA point, and specialty society meetings across ENT, pediatrics, rhinology, and pediatric nephrology), scientific education, and continuing medical education. Revenue is generated through one-time product sales at the pharmacy counter; no subscription, licensing, or SaaS pricing models are evident. The company is privately held with no disclosed revenue, headcount, or external funding rounds, and operates without any visible AI/ML capability or digital platform layer.
PharmaQ firmographics
Firmographics- Name
- PharmaQ
- Legal name
- PharmaQ A.E.
- Website
- https://pharmaq.gr
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmaQ A.E. is a privately held Greek pharmaceutical company (founded 2008, IASIS PHARMA group member) that develops and distributes OTC drugs, medical devices, natural remedies, and self-care products exclusively through pharmacies in Greece and Cyprus, serving doctors, pharmacists, and consumers across eight therapeutic categories.
- Ownership category
- akta.pro rank
PharmaQ industry classification
Industry- Product category
- OTC Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Pain Relief & Anti-Inflammatory (Analgesics) (HLAIADAA)
- akta.pro secondary industries
- Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC), Sleep, Stress & Mood Support (HLAIADAG), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)
Keywords
Where PharmaQ is headquartered
LocationHeadquarters
- HQ city
- Koropi
- HQ country
- Greece
- HQ region
- Europe
Offices1 record
Markets served
PharmaQ business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- OTC Pharmaceuticals: Over-the-counter (OTC) non-prescription drugs (ΜΗ.ΣΥ.ΦΑ.) distributed exclusively through pharmacies
- Medical Devices: Medical devices (Μedical devices) for various therapeutic applications
- Natural Remedies: Naturally derived remedies and natural health products
- Self-care Products: Self-healing/self-care health products for consumer use
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
PharmaQ product offering
Product offeringCore offering
PharmaQ develops, markets, and distributes innovative over-the-counter (OTC) pharmaceuticals, medical devices, naturally derived herbal remedies, and self-care products distributed exclusively through pharmacies. The company's portfolio spans 27+ products across eight therapeutic categories including dermatology, gastroenterology, allergology, pediatrics, and otorhinolaryngology, featuring proprietary formulations such as liposomal iron supplements, EMA-approved Chios Mastiha products, and unique combination sleep aids. Products target both the Greek/Cypriot domestic market and broader European/international markets.
Product overview
PharmaQ is a Greek pharmaceutical company (S.A.) founded in 2008 in Athens, operating as a member of the IASIS PHARMA group since 2010. The company offers 27 innovative pharmaceutical products and medical devices across 8 therapeutic categories: Allergology (2 products including Flutinasal), Self-care (6 products including Mastiha var.Chia line, Talorbin), Gastroenterology (2 products including Mastiha var.Chia capsules), General medicine (8 products including Ferrum Iasis, JustSleep, Athomer), Dermatology (8 products including Qpain, Sensibio, Acetochlor, Chemiderm, Flusterix), Pediatric (10 products including Stomatovis, Cue, Emofix, Rinopanteina), Oral Hygiene (1 product - Stomatovis), and Otorhinolaryngology (10 products including Nasodren, Nozovent, Quies, Rinopanteina Plus). The product portfolio includes OTC drugs (non-prescription medications), medical devices, naturally-derived remedies, and self-care health products. Key innovative products include Mastiha var.Chia (EMA-approved natural herbal medicine from Chios), Ferrum Iasis (liposomal iron technology), JustSleep (combination sleep aid that won Best in Pharmacy Awards 2018), and Qpain (topical anti-inflammatory with DMSO). All products are exclusively distributed through pharmacies and target both the Greek market and international markets.
Differentiator
Problem solved
Functional benefit
Brands
- JUSTSLEEP: Sleep aid product combining Melatonin 1mg, Valerian 200mg, and Hops 200mg for natural sleep solutions. Won Gold Award for Innovative New Pharmacy Product at Best in Pharmacy Awards 2018.
- Ferrum Iasis
- Mastiha var. Chia
Products and services
- Ferrum Iasis Enhanced pyrophosphate liposomal iron in microcapsules for iron supplementation. Innovative iron supplement for patients with iron deficiency.
- JustSleep Combination of Melatonin 1mg, Valerian 200mg, and Hops 200mg in a single tablet for reducing sleep onset time and providing restful sleep. Won Best in Pharmacy Awards 2018 Gold Award.
- Mastiha var.Chia Caps Natural Chios Mastiha in capsule form, an EMA-approved herbal medicine (since 2015) for digestive health.
- Mastiha var.Chia - Chios Mastiha Powder Chios Mastiha in powder form, 1080mg per sachet, package of 15 sachets. A 15-day natural solution for digestive health launched in November 2023.
- Mastiha var.Chia - Cutaneous Regenerative Gel Regenerative and soothing gel based on Chios Mastiha for skin application.
- Qpain Topical anti-inflammatory cutaneous solution containing diclofenac sodium 1.5% w/w with DMSO for enhanced absorption. Indicated for symptomatic relief of pain associated with osteoarthritis in superficial joints including the knee.
- Acetochlor Monochloroacetic acid solution for dermatological use.
- Athomer - Nasal Spray Nasal spray made with Aegean Sea seawater, the only nasal spray with seawater from the Aegean Sea.
- Chemiderm Dermatological cream product.
- Cue - Otologic Solution Otologic solution for pediatric use.
- Emofix - Haemostatic Barrier Ointment Haemostatic barrier ointment for wound care.
- Flusterix Dermatological product.
- Flutinasal Nasal spray for seasonal and chronic allergic rhinitis treatment.
- Rinopanteina - Nasal Ointment & Drops Innovative nasal ointment and drops with D-Panthenol, Vitamin A, oat proteins and mineral oils that lubricate, hydrate and protect the nasal mucosa. Helps re-epithelization and relieves symptoms of allergic, dry and pharmaceutical rhinitis.
- Rinopanteina Plus Nasal Spray Enhanced nasal spray version of Rinopanteina.
- Stomatovis - Paste & Mouthwash Stomatovis Paste is the only natural and effective treatment for ulcers from localized aphthae. Innovative composition with Panthenol, Aloe, Vitamins A & E and Zinc Oxide provides immediate pain relief, rapid tissue restoration. Stomatovis Mouthwash treats oral mucosa from stomatitis of various etiology and gingivitis.
- Talorbin Granules for oral solution containing Paracetamol 500mg, Ascorbic acid 200mg, and Pheniramine maleate 25mg per sachet.
- Sensibio Cream for dermatological use containing Fusidic acid 20mg and Betamethasone valerate 1mg per gram. Available in 15g and 30g tubes.
- Nasodren Product for sinusitis treatment.
- Nozovent Nasal dilator for respiratory support.
- Quies Hearing protection and relaxation product.
Companies that use PharmaQ
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
PharmaQ technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PharmaQ partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- IASIS PHARMAcorePharmaQ has been a member of the IASIS PHARMA group since 2010, which is an assertively expanding Greek pharmaceutical association. As part of the group, PharmaQ responds dynamically to new market challenges and benefits from shared resources and strategic direction.
- Mastiha Producers (Chios)coreExclusive representation of Chios Mastiha products - EMA approved natural remedy since 2015
- DMGminorInternational pharmaceutical partnership for product distribution
- GiulianiminorInternational pharmaceutical partnership for product distribution
- CeuticsminorInternational pharmaceutical partnership for product distribution
- QuiesminorInternational pharmaceutical partnership for hearing protection and relaxation products
- HartingtonminorInternational pharmaceutical partnership for product distribution
- Pharmacosmetic-DiafarmminorInternational pharmaceutical partnership for product distribution
- TemmlerminorInternational pharmaceutical partnership for product distribution
- PharmacureminorInternational pharmaceutical partnership for product distribution
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
PharmaQ competitors and assessment
Company assessmentDirect peers
- Help Pharmaceuticals: Greek pharmaceutical company focused on OTC and consumer health products distributed through pharmacies. Highly comparable as a Greek OTC pharma peer of similar scale, category breadth, and exclusive pharmacy-channel strategy.
- ELPEN Pharmaceutical: Greek pharmaceutical company producing OTC and prescription products with a focus on innovation and pharmacy distribution. Comparable as a Greek pharma peer emphasizing innovative formulations and pharmacy-channel sales.
- Galenica SA: Greek pharmaceutical manufacturer offering branded generics and OTC products through pharmacy channels. Comparable in geography, distribution model, and therapeutic category breadth as a domestic OTC pharma peer.
- Demo SA: Greek pharmaceutical manufacturer producing a broad portfolio of pharmaceutical products distributed in domestic and international markets. Comparable in geographic focus, product category diversity, and pharmacy-channel distribution.
Broad incumbents
- Haleon: Global consumer healthcare company (spun off from GSK) producing OTC products across pain, respiratory, oral health, and vitamin categories. Comparable as a broad multinational incumbent in the same OTC therapeutic categories PharmaQ serves.
- Perrigo Company: Global OTC pharmaceutical and consumer healthcare manufacturer producing store-brand and branded OTC products. Comparable as a peer in OTC pharmaceutical manufacturing and category innovation, though operating at much greater scale.
- Bayer Consumer Health: Global OTC consumer health division of Bayer covering pain, allergy, cough/cold, and dermatology. Comparable as a multinational incumbent competing in PharmaQ's core OTC categories across European markets.
- IASIS PHARMA: PharmaQ's parent group and a Greek pharmaceutical conglomerate representing multiple international pharma companies. Directly comparable as the broader group within which PharmaQ operates, providing shared distribution and corporate resources.
Emerging players
- Chiesi Farmaceutici: European specialty pharmaceutical company focused on respiratory, neonatology, and rare disease areas. Comparable as a specialty European pharma with overlapping respiratory focus and similar innovation-driven positioning.
Regional players
- Mastihashop (Chios Mastiha producers): Producer and retailer of Chios Mastiha-based natural products. Comparable as the source partner for PharmaQ's Mastiha var.Chia line, with overlapping natural-product and Chios Mastiha category exposure across digestive and self-care applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
PharmaQ social profiles
Digital presencePharmaQ financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaQ leadership team
Management profileNumber of profiles
PharmaQ funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaQ M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaQ
What does PharmaQ do?
PharmaQ develops, markets, and distributes innovative over-the-counter (OTC) pharmaceuticals, medical devices, naturally derived herbal remedies, and self-care products distributed exclusively through pharmacies. The company's portfolio spans 27+ products across eight therapeutic categories including dermatology, gastroenterology, allergology, pediatrics, and otorhinolaryngology, featuring proprietary formulations such as liposomal iron supplements, EMA-approved Chios Mastiha products, and unique combination sleep aids. Products target both the Greek/Cypriot domestic market and broader European/international markets.
Is PharmaQ a public or private company?
PharmaQ is a private company. It is classified as corporate owned and is currently operating.
When was PharmaQ founded?
PharmaQ was founded in 2008. It employs 11 to 50 people.
Where is PharmaQ based?
PharmaQ is headquartered in Koropi, Greece, in the Europe region.
How does PharmaQ make money?
Four revenue lines are on record. OTC Pharmaceuticals are the primary driver. The others are medical Devices, natural Remedies and self-care Products.
Who are PharmaQ's main competitors?
Direct peers on record are Help Pharmaceuticals, ELPEN Pharmaceutical, Galenica SA and Demo SA. Broad incumbents are Haleon, Perrigo Company, Bayer Consumer Health and IASIS PHARMA. Chiesi Farmaceutici is listed as an emerging player. Mastihashop (Chios Mastiha producers) is listed as a regional player.
Does PharmaQ have an API?
No public API is recorded for PharmaQ.
What industry is PharmaQ in?
PharmaQ's product category is OTC Pharmaceuticals. Its primary akta.pro industry code is HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics), with a secondary code of HLAIADAC, Allergy, Sinus & Respiratory (Non-Asthma). Its NAICS code is 325412 and its SIC code is 2834.